Clinical trials: Acne
Acne Vulgaris
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles.
- Trial name
- NCT00651469
- Testing
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
- Where
- 27 sites in United States
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Bayer
Acne Vulgaris
Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris
Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris
- Trial name
- NCT02938494
- Testing
- IDP-123 Lotion, Tazorac Cream, Vehicle Lotion
- Where
- 16 sites in United States
- Volunteers
- 210 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are…
- Trial name
- PROSES (NCT04820673)
- Testing
- Sarecycline
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
The primary objective of this study is to compare the efficacy, safety, and tolerability of IDP-120 Gel to IDP-120 Component A, IDP-120 Component B, and IDP-120 Vehicle Gel in subjects with moderate to severe acne vulgaris.
- Trial name
- NCT02537483
- Testing
- IDP-120 Gel, IDP-120 Component A, IDP-120 Component B
- Volunteers
- 350 people
- Sponsor
- Valeant Pharmaceuticals
Acne Vulgaris
A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
The goal of this study is to evaluate a complete topical acne regimen consisting of a prescription acne medication (Epiduo® Gel) and an acne-specific cleanser (Cetaphil® DermaControl™ Foam Wash) and moisturizer with sunscreen…
- Trial name
- NCT02249104
- Testing
- Adapalene/benzoyl peroxide gel, 0.1%/2.5%, Cetaphil Acne Regimen
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Galderma R&D
Acne Vulgaris
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post…
- Trial name
- LEAP (NCT05089708)
- Testing
- Trifarotene Cream, Trifarotene Vehicle Cream
- Where
- 25 sites in United States, Spain
- Volunteers
- 123 people
- Sponsor
- Galderma R&D
Acne
Epiduo Pediatric Acne Study
The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.
- Trial name
- NCT01138735
- Testing
- adapalene/benzoyl peroxide, Topical Gel Vehicle
- Where
- 25 sites in United States, Canada
- Volunteers
- 285 people
- Sponsor
- Galderma R&D
Acne
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
The purpose of the study is to determine the development of microbial resistance when using one of two topical acne therapies for the treatment of facial acne vulgaris.
- Trial name
- NCT00841776
- Testing
- Duac, Ziana gel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
This study is to evaluate the safety, pharmacokinetics, and treatment effect for topically applied CABTREO lotion in pediatric participants ages 9 to 11 years, 11 months with Acne Vulgaris.
- Trial name
- NCT07524946
- Testing
- CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%
The purpose of this study is to compare the safety and efficacy of 5% Dapsone Topical Gel, (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%.
- Trial name
- NCT00151541
- Testing
- Dapsone Topical Gel + adapalene gel 0.1%, Dapsone Topical Gel + benzoyl peroxide gel 4%, Dapsone Topical Gel + vehicle control
- Volunteers
- 301 people
- Sponsor
- Allergan
Acne Vulgaris
Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Therapeutic equivalence and safety study
- Trial name
- NCT02929719
- Testing
- Test., Aczone Gel 5%
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris
The objective of this study was to evaluate the efficacy and safety of the test formulation of adapalene gel 0.1% (PLIVA Research \& Development Ltd.) as compared to the already marketed formulation, Differin® (adapalene 0.1%)…
- Trial name
- NCT01182636
- Testing
- Adapalene, Differin®
- Where
- 22 sites in United States, Belize
- Volunteers
- 601 people
- Sponsor
- Teva Pharmaceuticals USA
Acne Vulgaris
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
The primary objective of this study is to compare the safety and efficacy of once daily application of IDP-123 Lotion to Tazorac Cream, 0.1%, Vehicle Lotion, and Vehicle Cream in subjects with moderate to severe acne vulgaris.
- Trial name
- NCT02525822
- Testing
- IDP-123 Lotion, Tazorac Cream, 0.1%,, Vehicle Cream
- Volunteers
- 210 people
- Sponsor
- Valeant Pharmaceuticals
Acne Vulgaris, Acne Vulgaris on the Face
Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris
This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study evaluates the efficacy and safety of a new concentration of the fixed-dose combination EF190 in women with moderate acne vulgaris over six…
- Trial name
- PANDORA (NCT06905210)
- Testing
- Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)
- Where
- 18 sites in Brazil
- Volunteers
- 531 people
- Sponsor
- Eurofarma Laboratorios S.A.
Acne Vulgaris
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
- Trial name
- NCT02815280
- Testing
- FMX-101, 4% minocycline foam, Vehicle Foam
- Where
- 36 sites in United States, Dominican Republic
- Volunteers
- 495 people
- Sponsor
- Vyne Therapeutics Inc.
Acne Vulgaris
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
The objective of this study is to compare the relative efficacy and safety of the test formulation Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to the marketed formulation Duac® Topical Gel…
- Trial name
- NCT01769664
- Testing
- Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, Duac® Topical Gel
- Volunteers
- 650 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study. The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate 1.2%/Benzoyl…
- Trial name
- NCT02005666
- Testing
- Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel
- Where
- 36 sites in United States, India
- Volunteers
- 850 people
- Sponsor
- Zydus Lifesciences Limited
MILD TO SEVERE ACNE VULGARIS
Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo
ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) gel, marketed by Medicis, The Dermatology Company®, is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01257906
- Testing
- CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL, ZIANA®, Vehicle Control
- Where
- India
- Volunteers
- 1,225 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne
Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne
This study will determine if the use of the BEAM device reduces the signs and symptoms of mild-to-moderate acne.
- Trial name
- NCT01162837
- Testing
- BEAM device
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Oregon Aesthetic Technologies
Acne Vulgaris
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
The objective of this study is to evaluate the therapeutic equivalence and safety of Adapalene and Benzoyl Peroxide 0.1%/2.5% Gel (Taro Pharmaceuticals Inc.) and Epiduo® (Adapalene and Benzoyl Peroxide 0.1%/2.5% Gel) (Galderma…
- Trial name
- NCT01742637
- Testing
- Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%, Epiduo® Gel
- Volunteers
- 2,008 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.